Dong Huaying, Wang Wei, Chen Ru, Zhang Yu, Zou Kejian, Ye Mulin, He Xionghui, Zhang Fan, Han Jing
Department of General Surgery, Hainan General Hospital, Haikou, Hainan 570311, P.R. China.
Int J Oncol. 2022 Aug;61(2). doi: 10.3892/ijo.2022.5382. Epub 2022 Jun 10.
Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that the TUNEL assay data shown in Fig. 6C were strikingly similar to images that had already appeared in Fig. 8B in another article that appeared in the journal Oncotarget [Chen W, Xu X-K, Li J-L, Kong K-K, Li H, Chen C, He J, Wang F, Li P, Ge X-S and Li F-C: MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget 8: 22783-22799, 2017]. Owing to the fact that the contentious data in the above article had already been published elsewhere prior to its submission to , the Editor has decided that this paper should be retracted from the Journal on account of a lack of confidence in the presented data. The authors did provide an explanation to account for the duplication of the data, although this was not accepted by the Editorial Board. The Editor apologizes to the readership for any inconvenience caused. [International Journal of Oncology 53: 1013-1026, 2018; DOI: 10.3892/ijo.2018.4467].
在本文发表后,一位关注此事的读者提醒编辑注意,图6C所示的TUNEL检测数据与发表在《肿瘤靶点》杂志[Chen W, Xu X-K, Li J-L, Kong K-K, Li H, Chen C, He J, Wang F, Li P, Ge X-S and Li F-C: MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget 8: 22783-22799, 2017]另一篇文章图8B中已经出现的图像极为相似。由于上述文章中有争议的数据在提交至本刊之前已在其他地方发表,编辑决定因对所呈现数据缺乏信心而从本刊撤回本文。作者确实对数据重复问题做出了解释,尽管编辑委员会未予认可。编辑就由此给读者带来的不便深表歉意。[《国际肿瘤学杂志》53: 1013-1026, 2018; DOI: 10.3892/ijo.2018.4467]